Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Aadi Bioscience, Inc. (AADI) reported a Q3 loss of $0.46 per share, which was in line with the Zacks Consensus Estimate. This is an improvement from the $0.60 per share loss reported a year ago. The company also exceeded revenue estimates.
November 06, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aadi Bioscience reported a Q3 loss of $0.46 per share, matching the Zacks Consensus Estimate and improving from last year's $0.60 loss. The company also exceeded revenue estimates.
The reported loss per share was in line with expectations, which is generally neutral. However, the improvement from the previous year's loss and the fact that revenue exceeded estimates are positive indicators. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100